Sero-Prevalence and Incidence of A/H1N1 2009 Influenza Infection in Scotland in Winter 2009-2010 by McLeish, Nigel J. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sero-Prevalence and Incidence of A/H1N1 2009 Influenza
Infection in Scotland in Winter 2009-2010
Citation for published version:
McLeish, NJ, Simmonds, P, Robertson, C, Handel, I, McGilchrist, M, Singh, BK, Kerr, S, Chase-Topping,
ME, Sinka, K, Bronsvoort, M, Porteous, DJ, Carman, W, McMenamin, J, Leigh-Brown, A & Woolhouse, MEJ
2011, 'Sero-Prevalence and Incidence of A/H1N1 2009 Influenza Infection in Scotland in Winter 2009-2010'
PLoS One, vol 6, no. 6, e20358, pp. -. DOI: 10.1371/journal.pone.0020358
Digital Object Identifier (DOI):
10.1371/journal.pone.0020358
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS One
Publisher Rights Statement:
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are
credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Sero-Prevalence and Incidence of A/H1N1 2009 Influenza
Infection in Scotland in Winter 2009–2010
Nigel J. McLeish1, Peter Simmonds1, Chris Robertson2,3, Ian Handel4, Mark McGilchrist5, Brajendra K.
Singh1, Shona Kerr6, Margo E. Chase-Topping7, Katy Sinka3, Mark Bronsvoort4, David J. Porteous6,
William Carman8, James McMenamin3, Andrew Leigh-Brown9, Mark E. J. Woolhouse1*
1Centre for Infectious Diseases, Ashworth Laboratories, University of Edinburgh, Edinburgh, United Kingdom, 2Department of Mathematics and Statistics, University of
Strathclyde, Glasgow, United Kingdom, 3Health Protection Scotland, Glasgow, United Kingdom, 4 Roslin Institute and Royal (Dick) School of Veterinary Studies, University
of Edinburgh, Edinburgh, United Kingdom, 5Health Informatics Centre, University of Dundee, Dundee, United Kingdom, 6Molecular Medicine Centre, University of
Edinburgh, Western General Hospital, Edinburgh, United Kingdom, 7Centres for Immunity, Infection and Evolution, Ashworth Laboratories, University of Edinburgh,
Edinburgh, United Kingdom, 8West of Scotland Specialist Virology Centre, Gartnavel General Hospital, Glasgow, United Kingdom, 9 Institute of Evolutionary Biology,
Ashworth Laboratories, University of Edinburgh, Edinburgh, United Kingdom
Abstract
Background: Sero-prevalence is a valuable indicator of prevalence and incidence of A/H1N1 2009 infection. However, raw
sero-prevalence data must be corrected for background levels of cross-reactivity (i.e. imperfect test specificity) and the
effects of immunisation programmes.
Methods and Findings: We obtained serum samples from a representative sample of 1563 adults resident in Scotland
between late October 2009 and April 2010. Based on a microneutralisation assay, we estimate that 44% (95% confidence
intervals (CIs): 40–47%) of the adult population of Scotland were sero-positive for A/H1N1 2009 influenza by 1 March 2010.
Correcting for background cross-reactivity and for recorded vaccination rates by time and age group, we estimated that
34% (27–42%) were naturally infected with A/H1N1 2009 by 1 March 2010. The central estimate increases to .40% if we
allow for imperfect test sensitivity. Over half of these infections are estimated to have occurred during the study period and
the incidence of infection in late October 2009 was estimated at 4.3 new infections per 1000 people per day (1.2 to 7.2),
falling close to zero by April 2010. The central estimate increases to over 5.0 per 1000 if we allow for imperfect test
specificity. The rate of infection was higher for younger adults than older adults. Raw sero-prevalences were significantly
higher in more deprived areas (likelihood ratio trend statistic = 4.92,1 df, P = 0.03) but there was no evidence of any
difference in vaccination rates.
Conclusions: We estimate that almost half the adult population of Scotland were sero-positive for A/H1N1 2009 influenza
by early 2010 and that the majority of these individuals (except in the oldest age classes) sero-converted as a result of
natural infection with A/H1N1 2009. Public health planning should consider the possibility of higher rates of infection with
A/H1N1 2009 influenza in more deprived areas.
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Introduction
Accurate knowledge of the fraction of the population infected
with influenza and how this changes through time is vital for
tracking epidemics and deciding upon intervention strategies [1].
Given widespread under-reporting of cases and largely unknown
variability in reporting patterns, sero-positivity (i.e. detection of
specific antibodies in serum) is typically the best available mea-
sure of population-level infection with influenza [2,3]. However,
estimates of sero-prevalence must be corrected for both a)
cross-reactivity in baselines titres resulting from prior infection or
immunisation with antigenically similar viruses (which gives the
serological test imperfect specificity), and b) the impact of con-
current A/H1N1 2009 vaccination programmes.
In Scotland, the first confirmed case of A/H1N1 2009 was
reported on 27 April 2009. Cases continued to be reported until 18
March 2010 and there were a total of 1542 hospitalisations and 69
deaths [4]. However, the estimated total number of cases in
Scotland reported to have consulted their GP with flu-like
symptoms was just 84,000 (95% confidence interval 79,000 to
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92,000) and this is likely to have been a very substantial under-
estimate of the true number of cases [5].
Two serological surveys for A/H1N1 2009 influenza have been
carried out in the UK during the epidemic, one during the early
phase [6] and one during the late phase [7], and there have been
several other sero-surveillance studies in other countries world-
wide [3,8]. The one previous report of adult sero-prevalence in
Scotland provided only estimates of raw sero-prevalences at a
single time point (March 2010), uncorrected for immunisation
rates and background cross-reactivity and covering only west
Scotland [9]. To address the limitations of that study and to ob-
tain substantive data on the timing of the spread of A/H1N1 2009
and changing incidences of infection during the epidemic, we
performed a large-scale sero-surveillance study in the adult
population of Scotland during the winter of 2009–2010, covering
the latter part of the A/H1N1 2009 epidemic and the immediate
post-epidemic period. We were able to correct the raw sero-
prevalence data for both background cross-reactivity and the
impact of the vaccination programme implemented in Scotland in
2009–2010. This allowed us to estimate the final size of the
epidemic (in terms of the fraction infected with A/H1N1 2009)
and incidence rates (new infections per 1000 persons per day)
during the study period. Using a multivariate approach, the se-
rological data were analysed by age, sex, geographical location and
social deprivation to identify risk factors for sero-positivity. Such
information is invaluable for assessing the need for and likely
impact of interventions to protect public health.
Methods
Ethics Statement
Written informed consent was obtained from all participants
who took part in the Generation Scotland Scottish Family Health
Study. This included consent to: ‘‘The information or samples that
I provide being used for future medical research into health, illness
and medical treatment.’’ This would have to be approved by a
properly constituted research ethics committee. The sero-preva-
lence project (ref no. GS09033) described here was approved
under the Generation Scotland Management, Access and Pub-
lication Policy. To satisfy the conditions of the written consent,
amendment 19 to 05/S1401/89, describing the use of serum
samples for the purposes of project GS09033, was submitted to the
Tayside Committee on Medical Research Ethics A. A favourable
ethical opinion of the amendment was received dated 30/10/09.
Samples
Serum samples were provided through the Generation Scotland
(GS) Biobank ([10]; see also www.generationscotland.org) from
anonymous volunteers in Scotland. A total of 1622 samples were
collected from general practices in East Scotland and the greater
Glasgow area and were accessed via GS collection centres at
Ninewells Hospital in Dundee and Gartnavel Hospital in Glasgow
over the periods 22 November 2009 to 18 April 2010 and 20 April
2010 to 28 June 2010 respectively.
Serology
Detection of A/H1N1 2009-specific antibodies was performed
using a microneutralisation (MN) assay based on the HPA
protocol [11]. Inactivated human sera were screened at a 1:40
dilution against the NIBRG122 SO-H1N1 isolate (100 TCID50
per well) obtained from the National Institute for Biological
Standards and Control and incubated at room temperature for
2 hours followed by the addition of MDCK cells and further
incubation at 37uC for 24 hours. Infectivity was determined by
staining cells for the IFA nucleoprotein by ELISA using a specific
monoclonal antibody, peroxidase-conjugated anti-mouse IgG and
substrate development. Plates were read at 450 nm, and optical
densities recorded by plate reader.
To estimate background cross-reactivity given previously re-
ported non-zero baseline sero-positivity in subjects uninfected
with A/H1N1 2009 influenza [6], we screened samples from the
University of Edinburgh clinical specimen archive. These com-
prised 267 anonymised samples from subjects drawn from the
general population (attendees of orthopaedic outpatient depart-
ments in Lothian) collected between March and June 2008 from
patients $21 years old.
We were not able to estimate test sensitivity directly; however,
the MN assay applied to A/H1N1 2009 influenza has an esti-
mated sensitivity of at least 83% [12].
Demographic data
Information provided from study subjects included age, sex,
postcode of residence (for subjects with a missing or invalid re-
sidential postcode the postcode of the referring GP was used), and
date of sample. We also scored subjects according to the Scottish
Index of Multiple Deprivation (www.scotland.gov.uk/Topics/
Statistics/SIMD) which is derived from the postcode. We also
considered additional postcode-derived variables: population den-
sity; urban-rural; and ethnicity (as percentage non-Caucasian).
There is a response bias among those who participate in Gen-
eration Scotland leading to an under-representation of males,
people in younger (,30) and older (.65) age groups and people in
the highest deprivation group, as measured by the Scottish Index
of Multiple Deprivation. Proportions in of study subject in various
demographic subgroups are recorded in Table 1. These biases
were com‘pensated for in data analysis by weighting samples back
to the population estimates obtained from the General Register
Office for Scotland (www.gro-scotland.gov.uk/statistics/theme/
population/estimates). Weights were constructed separately for
sex, age group in 5 year intervals, and deprivation quintiles and
combined using raking. All statistical analyses were based upon the
weighted sample using the survey package in R [13]. We note that
Table 1. Demographic characteristics of the study
population, compared with available population estimates for
the whole of Scotland (see text).
No. in
sample
% in
sample
% in
Scotland
Age group (years) 18–24 159 10.2 8
25–34 199 12.7 14
35–44 267 17.1 15
45–59 503 32.2 20
60–64 225 14.4 5
$65 210 13.4 15
Sex Female 932 59.6 52
Male 631 40.4 48
SIMD quintiles 1 (High) 199 12.7 20
2 255 16.3 20
3 287 18.4 20
4 479 30.7 20
5 (Low) 343 21.9 20
doi:10.1371/journal.pone.0020358.t001
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we do not have information on possible response biases with
respect to other risk factors (e.g. household size or occupation) that
might affect either the likelihood of influenza infection or the
likelihood of influenza vaccination in study subjects.
Vaccination data
Immunisation by A/H1N1 2009 vaccination began in Scotland
on 26 October 2010. Vaccination was targeted at people who were
in influenza clinical risk groups, including health care workers and
pregnant women. Unlike seasonal influenza vaccine the pandemic
vaccine was not available to all patients aged over 65, but only to
those in a clinical risk group. About 56% of people aged 65 years
and over are in at least one clinical risk group, while for adults
aged under 65 years 18% are in a clinical risk group. From late
December, vaccination was extended to all individuals aged be-
tween 6 months up to 5 years of age.
Vaccination records for individual study subjects were not
available. However, population-level data were available. In Scot-
land, vaccine uptake for individuals grouped by age was recorded
by GPs and weekly electronic extracts of data from all practices
were obtained. The first extract was received by Health Protection
Scotland on 15 November 2009 with 54% of practices reporting
and the final extract was available from 1 June 2010 with 95% of
practices reporting.
Statistical analysis
A total of 1622 samples were tested. Of these, 59 were excluded
from this analysis because they had a residential postcode from
outside Scotland or no valid postcode information was provided.
This left a total of 1563 samples (445 from Glasgow and 1118 from
East Scotland).
The data were first analysed using logistic multiple regression
models (generalised linear models with binomial errors) to identify
risk factors for sero-positivity. Two models were fitted. First, data
from all samples collected from 1 March 2010 onwards were
included in an analysis of post-epidemic patterns (since there were
very few new cases or vaccinations after that date). Risk factors
examined were age group, sex, region (Glasgow or East Scotland)
and deprivation score and the model allowed for clustering of
individuals within postcode zones. To this model we added, singly
and together, the postcode-level variables population density (as
quartiles), urban-rural (as the categories large urban, other urban,
small town and rural) and ethnicity (as percent non-Caucasian).
Second, data from all samples was analysed with collection date
included as a risk factor using a piecewise model with a log trend
(fitted separately for each age group) in risk with time prior to a
knot point at 1 March 2010 and a constant trend thereafter.
The second set of analyses estimated trends in sero-positivity
due to infection with A/H1N1 2009 by incorporating corrections
for background cross-reactivity and vaccination uptake. Here, it
was assumed that becoming sero-positive due to immunisation or
natural infection were independent and mutually exclusive events.
The test result for an individual subject was modelled as:
Ti,j*bern pi,j
 
pi,j~1{ 1{fj
 
1{uið Þspj
  ð1Þ
where Ti,j is the serological test result in subject i of age group j,
pi,j is the probability that subject i,j tested positive, fj is the
probability that subjects in age group j had been infected with A/
H1N1 2009, ui is the probability that patient i had been
vaccinated (estimated from age group-specific final vaccination
rates) and became sero-positive and spj is the serological test
diagnostic specificity for age group j (which reflects background
cross-reactivity).
For the Glasgow samples, because serological testing occurred
post-epidemic, fj in Equation (1) was assumed to be constant. For
the East Scotland samples, which were mainly collected during the
epidemic, fj was modelled as increasing to an asymptotic final
prevalence as:
pi,j tð Þ~1{ 1{fj tð Þ
 
1{uið Þspj
 
fj tð Þ~Aj 1{Bje{kt
  ð2Þ
where fj tð Þ is the probability of that a subject in age group j had
been infected with A/H1N1 2009 influenza by time t, Aj is the
asymptotic sero-prevalence in age group j, Aj 1{Bj
 
is the sero-
prevalence at the start of the study and k is the negative
exponential rate at which sero-prevalence approaches its asymp-
tote (assumed common to all age groups).
Vaccination uptake, ui, was estimated for each patient by
matching their age and sampling date to the relevant regional
uptake estimate data (lagged by 14 days to approximate the delay
in sero-conversion – see [14]; [5]). Diagnostic test specificity was
estimated as described above.
The models were estimated in a Bayesian framework using
MCMC simulation. Vague, uniform (0,1) prior distributions were
used for Aj and Bj in the East Scotland analysis, and an in-
formative prior distribution, gamma (3,100) was used for k. This
prior was based on simple empirical analysis of the GP pre-
sentation data (data collated from www.hps.scot.nhs.uk/resp/
publications.aspx) capturing the mean negative exponential rate of
case prevalence approaching its asymptote and giving broad
coverage of the variation evident in the different age groups.
Sensitivity of the final results to this prior distribution was explored
by varying its mean and variance.
The model was realised in JAGS [15] called from the R
Statistical System [13]. Parameter estimates on each of 10,000
iterations after a 10,000 iteration ‘burn-in’ period were used to
simulate sero-prevalence from infection withA/H1N1 2009 using
equations (1) and (2). MCMC chain convergence was assessed by
examination of 3 MCMC chains with dispersed initial values and
calculation of the Gelman-Rubin statistic [16].
Results
Background cross-reactivity
Of the 267 samples collected from subjects in 2008, a total of 9
(3.4%) showed neutralising antibodies to H1N1 using the criteria
described in the Methods section. Four of these were from 177
subjects between the ages 21–70 yrs (2.3% sero-positivity), and 5
from subjects .70 yrs old (5.6%). The difference between age
groups was not significant (exact P= 0.32). This result is consistent
with a low frequency of previous infection or immunisation with
antigenically similar H1N1 viruses and corresponds to an
estimated test specificity of 96.6% (95% confidence intervals
(CIs): 93.9–98.3%). However, because other studies (e.g. [6]) have
reported higher background cross-reactivity in older individuals
we repeated all analyses using the age-specific estimates.
Uncorrected sero-prevalence
Of the 1563 samples that met the inclusion criteria, 548
(35%) were sero-positive. Raw sero-prevalences (uncorrected for
Sero-Prevalence of A/H1N1 in Scotland
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immunisation, background cross-reactivity or imperfect test sen-
sitivity) at end of epidemic for the Glasgow sample ranged from
40% to 55% between age groups, with lowest sero-prevalences in
the 35–44 age category (Fig. 1a). For the East Scotland samples,
sero-prevalences substantially increased over the study period
(Fig. 1b).
Raw sero-prevalence for all samples collected after 1 March
2010 was 44% (95% CIs: 40–47%). Logistic regression analysis of
data from all samples collected after 1 March 2010 did not in-
dicate any effect of age, sex or geographical region on uncorrected
sero-prevalence (Table 2). However, there was a significant trend
for sero-prevalence to decrease with decreasing deprivation
(likelihood ratio trend statistic = 4.92, 1 df, P= 0.03). The odds
of an individual in the least deprived areas being sero-positive were
54% of the odds of an individual from the most deprived areas.
The deprivation effect was robust to inclusion of population
density, urban-rural, ethnicity or all three in the model, and none
of these variables were significantly associated with sero-preva-
lence. Logistic regression analysis of the full data set (allowing for
the temporal trends observed in the East Scotland data, Figure 1b)
Figure 1. Uncorrected sero-prevalence data. a) Estimates of sero-prevalence by age (in years) in the Glasgow area in spring 2010. Age groups
and their corresponding samples sizes are: 18–24 years old, 58; 25–34, 71; 34–44, 76; 45–59, 152; 60–64, 46; .65, 52. Binomial 95% confidence
intervals are shown. These results are not corrected for vaccination rates (see Figure 3a). b) Estimates of sero-prevalence by time in East Scotland
during winter 2009–2010. Samples sizes range from 16–79 per week (no estimate is given where for sample sizes below 10). Binomial 95% confidence
intervals are shown. These results are not corrected for vaccination rates (see Figure 3b).
doi:10.1371/journal.pone.0020358.g001
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gave very similar results (not shown) with an even stronger
relationship with deprivation (likelihood ratio trend statistic = 7.92,
1 df, P= 0.005).
Vaccination
From the beginning of the vaccination campaign in mid-
November 2009 the fraction of the general population vaccinated
rose at a decelerating rate until March 2010 (Fig. 2). Final vaccine
uptake in the adult population was 15% and increased with age,
ranging from ,5% in 16–25 year olds to .30% in .65 year olds
(Figure 2).
Corrected sero-prevalence
Estimates of age-specific sero-prevalences for the Glasgow
sample were corrected for the effects of immunisation and back-
ground cross-reactivity (Fig. 3a). Age-standardised, overall sero-
prevalence in the adult population was 34% (95% CIs: 27–42%).
Central estimates of sero-prevalence by age ranged from 49% in
16–25 year olds to 19% in .65 year olds (but with wide credible
intervals). There was a statistically significant decrease in corrected
sero-prevalence with age (Spearman’s rank correlation for
prevalence versus age ,0 in .95% model realisations), implying
that a greater proportion of uncorrected sero-positivity in older
age groups is accounted for by immunisation rather than natural
infection (Fig. 2).
Corrected age-specific sero-prevalences in the East Scotland
sample varied substantially through time (Fig. 3b). Estimates for
the start of the study in late October range from 7% to 16% across
age groups (but with wide credible intervals). Across all age groups,
approximately 60% infections occurred during the study period,
i.e. 40% occurred prior to late October 2009. Corrected sero-
prevalences at the end of the epidemic tend to be slightly lower
than those estimated for the Glasgow sample, but the confidence
intervals overlap for all age groups.
Allowing for a test sensitivity of 83% (see Methods) gave in-
creases in the sero-prevalence estimates of the order of 10%.
Allowing for age-specific background cross-reactivity (see Meth-
ods) led to only small adjustments in age-specific sero-prevalences
(all less than 62%; well within the credible intervals).
The age-standardised, average estimate of the rate of A/H1N1
2009 infection in the adult population of Scotland at the start of
the study period is 4.3 per 1000 persons per day (95% CIs: 1.2 to
7.2) falling close to zero by April 2010. Allowing for age-specific
background cross-reactivity led to negligible adjustments to this
Table 2. Odds ratios (OR) from a logistic regression model
fitted to data from all post-epidemic samples (collected after 1
March 2010).
OR LCL UCL P
Age group (years) 18–24 1.000 - -
25–34 0.763 0.421 1.381 0.372
35–44 0.854 0.477 1.529 0.595
45–59 0.755 0.454 1.253 0.277
60–64 0.914 0.488 1.710 0.778
$65 1.056 0.531 2.101 0.877
Sex Female 1.000 - -
Male 0.765 0.541 1.083 0.132
SIMD quintiles 1 (High) 1.000 - -
2 0.638 0.364 1.119 0.118
3 0.928 0.516 1.670 0.803
4 0.520 0.292 0.928 0.027
5 (Low) 0.536 0.304 0.946 0.032
Region East Scotland 1.000 - -
Glasgow 1.108 0.776 1.581 0.574
The model assumes the same age, gender and deprivation effects in the two
regions (interactions with region were all non-significant). LCL and UCL
represent lower and upper 95% confidence intervals respectively. SIMD
represents the Scottish Index of Multiple Deprivation (see text).
doi:10.1371/journal.pone.0020358.t002
Figure 2. Results from analysis of automated extracts of Scottish national vaccination data provided by Health Protection Scotland
(see main text). Cumulative percent general population vaccinated through time is shown by age group: 16–24 yrs old (red line); 25–34 (light
green); 35–44 (dark green); 45–59 (turquoise); 60–64 (blue); .65 (pink). Inclusion of additional practices late in the observation period results in a
slight (artefactual) dip in the uptake figures.
doi:10.1371/journal.pone.0020358.g002
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estimate. However, assuming a test sensitivity of 83% increased
estimated initial incidence to 5.6 per 1000 persons per day (95%
CIs: 1.6 to 9.4).
Discussion
The estimated test specificity in this study population was
96.6%, which is consistent with low levels of prior infection with
antigenically similar viruses or vaccines in this population. This
level of background cross-reactivity is somewhat lower than has
been reported elsewhere (e.g. [3], [6], [17], [18], [7]), especially in
older individuals. These differences may be due to natural
variation in the histories of influenza infection and vaccination
in different populations, though differences in test protocols could
also play a role.
The sero-prevalence data obtained between late October 2009
and mid-April 2010 from East Scotland indicate a substantial
increase (more than two-fold) in cumulative infection with A/
H1N1 2009 over the study period, at an initial rate (with some
variation across age groups) of at least 4.3 per 1000 persons per
day (but with wide confidence intervals), falling almost to zero by
April 2010 (Figure 3b). This is one of the first estimates of A/
H1N1 2009 incidence based on sero-surveillance data. Baguelin
et al. (2011) show the overall rate of change of sero-prevalence for
individuals 1–44 years old in England during the second pandemic
wave, though that study does not adjust vaccination uptake (which
the authors assume to be low).
Our analysis provides an estimate of final size of the 2009–2010
A/H1N1 2009 influenza epidemic (corrected for background
cross-reactivity and concurrent immunisation). At least 34% (95%
CIs: 27–42%) of the adult population of Scotland are estimated
to have been naturally infected with A/H1N1 2009 by 1 March
2010. This is somewhat higher than reported for adult populations
in England [5], New Zealand [8] and Pittsburgh PA [18]. Higher
adult sero-prevalences reported in England [7] and Norway [19]
were not corrected for the effects of vaccination programmes.
In our study there was a trend for corrected sero-prevalence to
decrease with age but there was no evidence of differences be-
tween sexes or between the two regions of Scotland included in the
study. Our data are limited to adults: in children, especially school-
age children, rates of natural infection are likely to have been
considerably higher [8,18,19]. Importantly, our results do suggest
that rates of infection with A/H1N1 2009 were higher in more
deprived areas, based on the observations that 1) sero-prevalence
was significantly higher in more deprived areas but 2) there is no
evidence of any relationship between deprivation and immunisa-
tion rates [20]. This effect it is not explained by differences in local
population density or between urban and rural areas or by
differences in ethnicity. No relationship between sero-prevalence
and socioeconomic status was found in a study in Australia [21].
Sero-prevalence overall (resulting from a combination of natural
infection with influenza A/H1N1 2009, the effects of immunisa-
tion programme instigated in late 2009 and low background levels
of cross-reactivity) in the adult population of Scotland is estimated
to have been at least 44% (95% CIs: 40–47%) by early 2010. This
would be expected to generate a significant degree of herd
immunity and so, in the absence of significant change in the
antigenicity of the virus, protect the population from a major
epidemic of A/H1N1 2009 in the 2010–2011 influenza season.
However, any such effect would be reduced if: 1) the cut-off
antibody titre (1 in 40 dilution) used does not necessarily imply
immunity in adults: 2) antibody level and hence protection in
vaccinated adults has waned faster than anticipated; 3) relaxation
of the pandemic control programme has led to higher transmission
rates than in 2009–2010. Further work is needed to examine these
possibilities.
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